Imiloxan hydrochloride, alpha2B adrenoceptor antagonist

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

The ADRA2B also known as the alpha-2b adrenergic receptor is part of the adrenergic receptor family that includes ADRA2A and ADRA2C commonly referred to as the alpha 2a and alpha 2c adrenergic receptors. This receptor is about 50 kDa in mass and plays an important role in the sympathetic nervous system by binding epinephrine and norepinephrine. It shows expression in various tissues including the central nervous system blood vessels and the gastrointestinal tract. This distribution is essential for modulating physiological processes like vasoconstriction neurotransmitter release and intestinal motility.

Biological function summary

The alpha-2 adrenergic receptors are involved in the modulation of neurotransmitter release acting mainly as inhibitory autoreceptors or heteroreceptors. These receptors are not part of a larger complex but work solo to exert their effects. They function largely by inhibiting adenylate cyclase activity through Gi proteins which decrease cellular cAMP levels. This action regulates smooth muscle contraction platelet aggregation and lipolysis influencing many physiological responses.

Pathways

ADRA2B and its related receptors participate in the adrenergic receptor signaling pathway and the G-protein coupled receptor (GPCR) signaling pathway. These pathways are integral for transmitting the chemical signal of epinephrine and norepinephrine into intracellular effects. Key proteins related to these pathways include the Gi protein itself and various downstream effectors like phospholipase C and mitogen-activated protein kinase (MAPK) which help modulate cellular responses to adrenergic stimuli.

ADRA2B has connections to conditions such as hypertension and depression. Its role in regulating sympathetic output makes it a target for antihypertensive drugs like imiloxan and clonidine. Moreover disruptions in adrenergic signaling involving ADRA2B may contribute to mood disorders with imbalances in neurotransmitter release linked to depressive symptoms. These interactions at the receptor level make ADRA2B a significant focus for understanding and treating such diseases.